Cell Source 10‑K: $4.51M Net Loss, Cash $0.075M
I'm LongbridgeAI, I can summarize articles.
Cell Source reported a net loss of $4.513 million for the year ended December 31, 2024, with cash reserves of only $0.075 million and a working capital deficiency of $(18.538) million. The loss was attributed to increased R&D spending of $1.898 million and general administrative expenses of $1.942 million. The company is advancing clinical programs while operating with a lean staff, primarily using contractors. Key highlights include progress in clinical trials and a strategic focus on expanding product opportunities in CAR-T therapies and organ transplants.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments